Healthcare services group Uniphar has reported a good start to 2024, with performance in the first four months in line with the Board's expectations.
In a trading update issued ahead of its AGM today, the company said it remains well positioned to deliver organic gross profit growth across each division in line with previous guidance and to deliver expectations for the full year.
In today's AGM statement, Maurice Pratt, Chairman of Uniphar, said last year was another successful year for the company.
He said the company achieved a significant milestone of doubling 2018 pro-forma EBITDA ahead of the timeframe committed to at the time of IPO.
"We also announced a new ambitious target of growing Group EBITDA to €200m over the medium-term. This will be achieved through a combination of strong organic growth complemented with acquisitions that meet our disciplined strategic and financial criteria," Mr Pratt said.
During the year, the company also reorganised into three new divisions - Uniphar Supply Chain & Retail, Uniphar Medtech, and Uniphar Pharma - to better capitalise on growth opportunities and align with its customers and stakeholders.
Maurice Pratt said that M&A remains a key component of Uniphar's growth strategy and the group completed the acquisitions of the McCauley Pharmacy Group and certain assets from Pivot Digital during the year.
